IMPA1
Inositol monophosphatase 1
As of the edition of 20 October 2026, IMPA1 (inositol monophosphatase 1, UniProt P29218) has 2 drugs tested at it and 9 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P29218
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 13
- Disease areas
- Nervous system; Mental health; Cancer; Inherited and neonatal; Injuries; Blood and lymph; Nutrition and metabolism; Chemically induced
- Registered trials of its drugs
- 65
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lithium carbonate | Marketed | Phase 4 | none listed |
| Lithium citrate anhydrous | Marketed | No phase stated | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 8 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| Pfizer | Route B |
The other 8 companies at IMPA1
In the product9 companies in all; 8 are not named here, and no score is.
See the 9 companies at IMPA1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.